JAK-STAT pathway inhibition and their implications in COVID-19 therapy

S Satarker, AA Tom, RA Shaji, A Alosious… - Postgraduate …, 2021 - Taylor & Francis
… increases with time, more and more efforts are made to pave a way out for the therapeutic
in COVID-19 patients, it drives our focus onto the signaling cascades of the JAK/STAT pathway

[HTML][HTML] Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets

M Farahani, Z Niknam, LM Amirabad… - Biomedicine & …, 2022 - Elsevier
… Nafamostat is another TMPRSS2 inhibitor that in a mouse model of COVID-19 reduced
SARS-CoV-2 pulmonary infection [17]. A neutralizing antibody directed against the viral S protein …

Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies

G Ragia, VG Manolopoulos - European journal of clinical pharmacology, 2020 - Springer
COVID-19 test result. Another TMPRSS2 inhibitor with therapeutic potential for treatment of
COVID-19 is … drug for indications unrelated to corona virus and used in Asian countries as a …

Targeting the PI3K/Akt/mTOR pathway: A therapeutic strategy in COVID-19 patients

R Abu-Eid, FJ Ward - Immunology letters, 2021 - Elsevier
… of different components of the PI3K/Akt/mTOR pathway did not show the same significant …
as therapeutic targets in COVID-19, using the inhibitor SF2523 (a small molecule inhibitor that …

The role and therapeutic potential of NF-kappa-B pathway in severe COVID-19 patients

A Hariharan, AR Hakeem, S Radhakrishnan… - …, 2021 - Springer
… result in a reduction in the cytokine storm and alleviate the severity of COVID-19. Inhibition
of NF-κB pathway has a potential therapeutic role in alleviating the severe form of COVID-19. …

PI3K/AKT signaling pathway: a possible target for adjuvant therapy in COVID-19

MR Khezri - Human Cell, 2021 - Springer
… , which have been shown to inhibit PI3K/AKT signaling pathway and ultimately suppress
inflammation [10], along with antiviral drugs to combat COVID-19 can be considered. …

Cellular and molecular pathways of COVID-19 and potential points of therapeutic intervention

JP Hussman - Frontiers in pharmacology, 2020 - frontiersin.org
… , and DHA/EPA, pasireotide), as well as inhibitors targeted toward molecular mediators of
the maladaptive COVID-19 immune response (eg, IL-6, TNF-α, IL-17, JAK, and CDK9). …

JAK inhibition as a new treatment strategy for patients with COVID-19

F Seif, H Aazami, M Khoshmirsafa, M Kamali… - International archives of …, 2020 - karger.com
… other potential JAKinibs and novel anti-inflammatory combination therapies that affect the
JAK-STAT pathway in patients with COVID-19. Since the combination of MTX and baricitinib …

The potential of JAK/STAT pathway inhibition by ruxolitinib in the treatment of COVID-19

BG Bagca, CB Avci - Cytokine & growth factor reviews, 2020 - Elsevier
inhibitor, and is known to interfere with the JAK / STAT signaling pathway, one of the critical
cellular signaling pathways … SARS-CoV-2 and the COVID-19 pandemic, and then focuses on …

Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab

A Rambaldi, G Gritti, MC Micò, M Frigeni, G Borleri… - Immunobiology, 2020 - Elsevier
… syndrome-associated coronavirus-2 (… pathway activation and has anticoagulant effects.
In this study, the first time a lectin-pathway inhibitor was used to treat COVID-19, six COVID-19